Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy
To assess the impact of carcinoma in situ (CIS) on oncologic outcomes in patients who underwent radical cystectomy, with a focus on those who received neoadjuvant chemotherapy (NAC) including patients with down-staging to ≤ pT1cancer after chemotherapy.
Materials and methods
All patients who underwent radical cystectomy for urothelial cancer with curative intent from 1985 to 2011 were included. The impact of CIS on recurrence free and overall survival (OS) was assessed in the whole cohort and a subgroup who received NAC as well as those with response to chemotherapy and down-staging to ≤ pT1.
A total of 2518 patients with a median follow-up period of 9 years were included. Among all, 1397 (55.5%) had concomitant CIS on final pathology. CIS was associated with high risk pathologic features including high-grade disease, multifocality, and nodal involvement as well as worse recurrence free survival (RFS) with no impact on OS. We did not find a significant association between CIS and oncologic outcomes in a subset of patients who received NAC including those with down-staging to ≤ pT1 disease. In multivariate analysis, CIS had no association with either recurrence free or OS.
Concomitant CIS in radical cystectomy specimens is associated with decreased RFS; however, in multivariate analysis, it was not an independent predicting factor of oncologic outcomes. Moreover, the impact of CIS on oncologic outcomes in a subset of patients who received NAC was insignificant.
KeywordsCarcinoma in situ Cystectomy Neoadjuvant therapy Survival Urinary bladder neoplasms
Compliance with ethical standards
Conflict of interest
All authors declare no conflicts of interests.
All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the Helsinki declaration.
Informed consent was obtained from all individual participants included in the study.
- 17.International Collaboration of T, Medical Research Council Advanced Bladder Cancer Working P, European Organisation for R, et al (2011) International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 29:2171CrossRefGoogle Scholar
- 20.Zargar H, Zargar-Shoshtari K, Lotan Y et al (2015) Final Pathologic stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer: does pT0 predict better survival than pTa/Tis/T1? J Urol 195(4):886–893Google Scholar
- 22.Bostrom PJ, van Rhijn BWG, Fleshner N et al (2010) Staging and staging errors in bladder cancer. Eur Urol Suppl 9:2–9Google Scholar
- 23.Saadat SH, Al-Tawil MO (2011) Risk factors for disconcordance between pre and post radical cystectomy stages. Urol J 8:291Google Scholar